SEI Investments’s Viridian Therapeutics VRDN Stock Holding History

SEI Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$267K	Sell	14,535 -51,242	-78%	-$826K	﹤0.01%	2915
2026 Q1	$1.29M	Buy	65,777 +35,459	+117%	+$1.05M	﹤0.01%	2226
2025 Q4	$943K	Buy	30,318 +18,762	+162%	+$515K	﹤0.01%	2208
2025 Q3	$249K	Buy	11,556 +1,046	+10%	+$18.9K	﹤0.01%	2535
2025 Q2	$147K	Buy	+10,510	New	+$143K	﹤0.01%	2631
2023 Q3	–	Sell	-9,934	Closed	-$236K	–	2700
2023 Q2	$236K	Sell	9,934 -27,412	-73%	-$703K	﹤0.01%	2419
2023 Q1	$950K	Buy	37,346 +18,410	+97%	+$590K	﹤0.01%	1892
2022 Q4	$553K	Buy	+18,936	New	+$436K	﹤0.01%	1971
2018 Q3	–	Sell	-93	Closed	-$9K	–	3450
2018 Q2	$9K	Hold	93	–	–	﹤0.01%	3039
2018 Q1	$10K	Buy	+93	New	+$10.1K	﹤0.01%	2883

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SEI Investments's VRDN Position: Q2 2026 in Review

SEI Investments reduced its Viridian Therapeutics (VRDN) stake by 78% in Q2 2026, selling an estimated $826K and leaving 14,535 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #2915.

SEI Investments first reported a position in VRDN in Q1 2018 and has held it in 10 quarters since. The position peaked at $1.29M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

SEI Investments held 14,535 shares of Viridian Therapeutics worth $267K as of Q2 2026.
SEI Investments sold 51,242 Viridian Therapeutics shares in Q2 2026, an estimated $826K.
Viridian Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2915 holding.
SEI Investments first reported a position in Viridian Therapeutics in Q1 2018 and has held it in 10 quarters since.
SEI Investments's Viridian Therapeutics position peaked at $1.29M in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.